Kalaris Therapeutics (KLRS) Misses Q2 EPS by 61c

Kalaris Therapeutics (NASDAQ: KLRS) reported Q2 EPS of ($0.61).

For earnings history and earnings-related data on Kalaris Therapeutics (KLRS) click here.

You May Also Be Interested In

• AppFolio (APPF) Tops Q2 EPS by 2c ; Offers Guidance
• First Resource Bank (FRSB) Tops Q2 EPS by 92c
• Boston Beer Co. (SAM) Misses Q2 EPS by 131c ; Offers Guidance